Integra LifeSciences Holdings Corporation $IART Shares Purchased by Tejara Capital Ltd

Tejara Capital Ltd increased its position in shares of Integra LifeSciences Holdings Corporation (NASDAQ:IART) by 42.6% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 171,813 shares of the life sciences company’s stock after buying an additional 51,300 shares during the quarter. Tejara Capital Ltd owned about 0.22% of Integra LifeSciences worth $2,134,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Osaic Holdings Inc. boosted its holdings in shares of Integra LifeSciences by 36.6% in the second quarter. Osaic Holdings Inc. now owns 4,119 shares of the life sciences company’s stock valued at $51,000 after acquiring an additional 1,104 shares during the period. GAMMA Investing LLC increased its holdings in shares of Integra LifeSciences by 145.9% in the 4th quarter. GAMMA Investing LLC now owns 6,307 shares of the life sciences company’s stock valued at $78,000 after acquiring an additional 3,742 shares during the period. Tower Research Capital LLC TRC raised its position in Integra LifeSciences by 595.6% in the 2nd quarter. Tower Research Capital LLC TRC now owns 7,958 shares of the life sciences company’s stock valued at $98,000 after purchasing an additional 6,814 shares during the last quarter. Amundi raised its position in Integra LifeSciences by 17,193.8% in the 2nd quarter. Amundi now owns 11,068 shares of the life sciences company’s stock valued at $150,000 after purchasing an additional 11,004 shares during the last quarter. Finally, State of Wyoming boosted its stake in Integra LifeSciences by 84.0% during the 2nd quarter. State of Wyoming now owns 12,953 shares of the life sciences company’s stock worth $159,000 after purchasing an additional 5,914 shares during the period. Hedge funds and other institutional investors own 84.78% of the company’s stock.

Analyst Upgrades and Downgrades

IART has been the topic of a number of recent research reports. Weiss Ratings upgraded shares of Integra LifeSciences from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday. Truist Financial lowered their price target on Integra LifeSciences from $13.00 to $12.00 and set a “hold” rating on the stock in a report on Wednesday, April 15th. Argus restated a “hold” rating on shares of Integra LifeSciences in a research report on Wednesday, April 15th. Citigroup upped their price objective on Integra LifeSciences from $9.00 to $11.00 and gave the company a “sell” rating in a research note on Wednesday, May 6th. Finally, Wall Street Zen raised Integra LifeSciences from a “hold” rating to a “buy” rating in a research report on Saturday, May 9th. Three investment analysts have rated the stock with a Hold rating and three have given a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Reduce” and a consensus price target of $12.75.

Integra LifeSciences Stock Down 2.7%

IART stock opened at $14.50 on Friday. The stock has a market capitalization of $1.13 billion, a PE ratio of -2.24 and a beta of 1.08. The company has a fifty day moving average of $10.52 and a 200-day moving average of $11.65. The company has a debt-to-equity ratio of 1.75, a quick ratio of 1.95 and a current ratio of 3.38. Integra LifeSciences Holdings Corporation has a one year low of $8.70 and a one year high of $16.49.

Integra LifeSciences (NASDAQ:IART) last posted its quarterly earnings results on Tuesday, May 5th. The life sciences company reported $0.54 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.41 by $0.13. Integra LifeSciences had a negative net margin of 30.15% and a positive return on equity of 17.42%. The firm had revenue of $391.92 million during the quarter, compared to analysts’ expectations of $381.81 million. During the same period in the prior year, the company posted $0.41 earnings per share. The firm’s revenue for the quarter was up 2.4% on a year-over-year basis. Integra LifeSciences has set its FY 2026 guidance at 2.400-2.500 EPS and its Q2 2026 guidance at 0.440-0.520 EPS. As a group, analysts expect that Integra LifeSciences Holdings Corporation will post 2.44 EPS for the current year.

About Integra LifeSciences

Integra LifeSciences Corporation is a global medical technology company specializing in products and innovations for neurosurgery, regenerative medicine and reconstructive procedures. The company develops and markets surgical instruments, implants and advanced wound care solutions designed to support tissue repair and functional recovery. Its product portfolio includes collagen-based matrices, dural substitutes, hemostatic agents and specialized spinal and peripheral fixation devices.

Founded in 1989 and headquartered in Plainsboro, New Jersey, Integra has expanded its capabilities through targeted acquisitions and internal research efforts.